DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors
News 19.11.2026 Cologne, Germany, November 19, 2026 – DISCO Pharmaceuticals (“DISCO”) today announced a strategic collaboration and option- to-license agreement with AbbVie to discover and develop novel AND-gated bispecific therapeutics for solid tumors with high unmet medical need. Under the terms of the agreement, DISCO will receive $40 million in upfront payments and is...